Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VBL Therapeutics (VBL), a clinical-stage biotechnology company into the development of novel treatments for immune-inflammatory diseases and cancer, has released preclinical data demonstrating that VB-201 regulates inflammatory pathways and may effectively control inflammatory responses associated with autoimmune diseases and atherosclerosis.
Subscribe to our email newsletter
VBL claimed that VB-201 is the first in a new class of drugs and the lead candidate of several proprietary phospholipid analogs from its proprietary Lecinoxoid family that were designed to be orally available, anti-inflammatory medicines.
In the study the researchers have assessed the anti-inflammatory activity of VB-201 both in-vivo and in-vitro. Both in-vitro and in-vivo, researchers examined the effect of VB-201 on cytokine levels produced by activated mouse and human dendritic cells and on the migration of human and mouse monocytes toward a wide range of chemokines and inflammatory insults.
The study results suggested that VB-201 has inhibited the production of IL-12/23 common chain p40 by activated dendritic cells. VB-201 also impaired migration of monocytes toward several chemo-attractants and inflammatory insults.
Eyal Breitbart, vice president of research at VBL, said: “Today’s data demonstrating that VB-201 has anti-inflammatory activity suggest that it may have utility in the treatment of a range of autoimmune diseases, including atherosclerosis, rheumatoid arthritis, multiple sclerosis, psoriasis and inflammatory bowel disease.”
Dror Harats, CEO of VBL, said: “We are honored to have the opportunity to present this data on VB-201 at a meeting widely recognised as a forum for scientific dialogue. These data contribute to the growing body of knowledge about VB-201 and we look forward to the results of our ongoing phase 2 clinical trial in patients with psoriasis.”